De novo design and Rosetta‐based assessment of high‐affinity antibody variable regions (Fv) against the SARS‐CoV‐2 spike receptor binding domain (RBD). Issue 2 (8th October 2022)

• Record Type: Journal Article
• Authors: Boorla, Veda Sheersh; Chowdhury, Ratul; Ramasubramanian, Ranjani; Ameglio, Brandon; Frick, Rahel; Gray, Jeffrey J.; Maranas, Costas D.
• Is Part Of: Proteins. Volume 91:Issue 2(2023)
• Page Start: 196
• Page End: 208
• Publication Date: 2022-10-08
• Subjects: antibody design -- computational protein design -- Fv antibody fragments -- Ig variable region -- neutralizing antibodies; Proteins -- Periodicals; Proteins -- Periodicals; 572.6
• DOI: 10.1002/prot.26422
• Languages: English
• ISSNs: 0887-3585

Abstract

Abstract: The continued emergence of new SARS‐CoV‐2 variants has accentuated the growing need for fast and reliable methods for the design of potentially neutralizing antibodies (Abs) to counter immune evasion by the virus. Here, we report on the de novo computational design of high‐affinity Ab variable regions (Fv) through the recombination of VDJ genes targeting the most solvent‐exposed hACE2‐binding residues of the SARS‐CoV‐2 spike receptor binding domain (RBD) protein using the software tool OptMAVEn‐2.0 . Subsequently, we carried out computational affinity maturation of the designed variable regions through amino acid substitutions for improved binding with the target epitope. Immunogenicity of designs was restricted by preferring designs that match sequences from a 9‐mer library of "human Abs" based on a human string content score. We generated 106 different antibody designs and reported in detail on the top five that trade‐off the greatest computational binding affinity for the RBD with human string content scores. We further describe computational evaluation of the top five designs produced by OptMAVEn‐2.0 using a Rosetta‐based approach. We used Rosetta SnugDock for local docking of the designs to evaluate their potential to bind the spike RBD and performed "forward folding" with DeepAb to assess their potential to fold into the designed structures. Ultimately, our results identified one designed Ab variable region, P1.D1, as a particularly promising candidate for experimental testing. This effort puts forth a computational workflow for the de novo design and evaluation of Abs that can quickly be adapted to target spike epitopes of emerging SARS‐CoV‐2 variants or other antigenic targets.